Executive Summary

MARKET SIZE 2025
USD 8.0bn
~7% CAGR to '30 [Fortune BI 2025]
Fortune BI 2025
ETC SHARE 2025
~75%
Tender-driven [Stellapharm 2025]
Stellapharm 2025
DOM. TENDER SHARE
26.2%
VND 34.7tn 2023 base [VSS 2024]
VSS 2024
2030 DOM. TARGET
70%
Value share [Decision 1165 2023]
Decision 1165 2023

Localization is the structural story

Decision 1165 targets domestic drug supply at 80% of demand and 70% of market value by 2030 [Decision 1165 2023]; locally produced API reaches a more modest 20% share. Circular 40/2025/TT-BYT explicitly rewards EU-GMP-certified domestic supply in hospital tenders [MoH 2025], converting the certification race into pricing power. The 2025-27 window decides which domestic majors lock in tender share before Tier-1 lot competition stabilises.

Biosimilars open the second leg

Celltrion launched Remsima (infliximab) and Herzuma (trastuzumab) into Vietnam in 2024-25 [Celltrion 2025]. Nanogen's Stimus (darbepoetin alfa biosimilar) is in late-stage hospital trials [Nanogen 2025]. With biologics at ~USD 7.3 bn within the broader pharma value chain [Medpath 2025] and ASP discounts of 50-70% versus reference biologics [InsightAce 2025], biosimilar penetration becomes the 2027-30 margin lever for both ETC tender wins and BHYT cost containment.

Vietnam pharma market trajectory
USD bn · 2023-2030F
USD BN
0 4 8 12 16 6.8 7.4 8.0 8.7 9.4 10.2 12.0 2023 2024 2025 2026F 2027F 2028F 2030F
SOURCE: FORTUNE BI 2025, STELLAPHARM 2025, KIRA TRIANGULATION · KIRA RESEARCH 2026
Stellapharm 2025 = Stellapharm "Vietnam pharma trends 2025-2030" Briefing · VSS 2024 = Vietnam Social Security Drug Tender Summary 2023 (published 2024) · Decision 1165 2023 = PM Decision 1165/QĐ-TTg National Pharma Strategy to 2030 · Celltrion 2025 = Celltrion Vietnam Biosimilar Launch Press 2024-25 · Nanogen 2025 = Nanogen Stimus Clinical Trial Bulletin 2025 · Medpath 2025 = Medpath "Celltrion Vietnam biopharma" 2025 · InsightAce 2025 = InsightAce Trastuzumab Biosimilar Report 2025 · MoH 2025 = Bộ Y tế Circular 40/2025/TT-BYT · Fortune BI 2025 = Fortune Business Insights "Vietnam Pharmaceuticals 2032" · Kira estimates = KIRA in-house analyst triangulation

Demand backbone: demographics, coverage, spend

Vietnam's 102m-person economy expands at 7%-plus through the forecast window [IMF WEO 2026], with health spending and BHYT coverage compounding on top. Pharma spend per capita sits near USD 80 in 2025 [Kira estimates] — well below Thailand and Malaysia peers, and the convergence path is the underlying demand pull.

Population & ageing

Vietnam's population reached ~102m in 2025 [GSO 2025], with 14% over 60 and rising to ~20% by 2035 [GSO 2025]. The ageing curve translates directly into chronic-disease prescription volumes — diabetes, cardiovascular, oncology — the same therapy windows where biosimilar entry is now economically meaningful.

BHYT coverage

BHYT (compulsory health insurance) covers ~93% of the population [VSS 2024], anchoring the ETC channel. The 2025 abolition of hospital-rank distinction in drug-use eligibility [Circular 37/2024 2024] expanded access to higher-tier therapies at lower-tier facilities — the demand pull for biosimilars and high-end generics widens correspondingly.

Spend trajectory

Total health spend tracked 6%+ of GDP in 2025 [Kira estimates from GSO + MoH bulletins]. Pharma spend per capita rises to ~USD 110 by 2030 in our base case [Kira estimates], driven by ETC formulary expansion plus OTC retail consolidation. The relative-price tailwind versus brand-imports compresses; volume becomes the dominant growth lever.

Vietnam macro signals
% YoY · 2023-2027F
% YoY
0 2.5 5.0 7.5 10.0 7.8 8.0 2023 2024 2025 2026F 2027F GDP Pharma CAGR
SOURCE: GSO 2025, IMF WEO 2026, FORTUNE BI 2025, KIRA TRIANGULATION · KIRA RESEARCH 2026
GSO 2025 = Tổng cục Thống kê Population & Labour Bulletin 2025 · IMF WEO 2026 = IMF World Economic Outlook April 2026 (Vietnam profile) · VSS 2024 = Vietnam Social Security BHYT Coverage Bulletin 2024 · Circular 37/2024 2024 = MoH Circular 37/2024/TT-BYT BHYT Drug Payment · Kira estimates = KIRA in-house analyst triangulation